1. Introduction {#s0005}
===============

Patients with Corona virus disease 2019 (COVID-19) have been reported prone to develop thrombotic and thromboembolic disease \[[@bb0005], [@bb0010], [@bb0015], [@bb0020]\]. Microthrombosis has been suggested to contribute to both respiratory failure and neurological complications \[[@bb0025],[@bb0030]\] and emerging data describe coagulation abnormalities as a marker of poor prognosis \[[@bb0035], [@bb0040], [@bb0045]\].

Low molecular weight heparins (LMWH) are often prescribed to decrease the risk of thromboembolic complications in hospitalized patients and treatment with LMWH was recently shown to reduce mortality in high-risk patients with COVID-19 \[[@bb0050]\]. However, data is limited on the mechanisms underlying the coagulation deficits associated with COVID-19 and how they are affected by LMWH.

Thromboelastography (TEG) offers a comprehensive assessment of coagulation in whole blood samples, describing plasmatic coagulation as well as platelet function and fibrinolysis. Furthermore, the addition of heparinase to the sample eliminates the iatrogenic heparin effect in blood samples thus allowing estimation of the effect of LMWH.

The aim was to characterize coagulation abnormalities and the effect of LMWH with respect to TEG profile with and without heparinase, anti-factor Xa activity and clinical manifestations (i.e. bleeding and thrombosis) in 31 COVID-19 patients admitted to intensive care units at Uppsala University Hospital, Uppsala, Sweden.

2. Materials and methods {#s0010}
========================

The study was approved by the National Ethical Review Agency (EPM; No. 2020--01623). Informed consent was obtained from the patient, or next of kin if the patient was unable give consent. The Declaration of Helsinki and its subsequent revisions were followed. The protocol of the study was registered a priori (ClinicalTrials ID: [NCT04316884](NCT04316884){#ir0005}). STROBE guidelines were followed for reporting.

This prospective observational study was performed at a mixed surgical/medical intensive care unit (ICU) at Uppsala University Hospital, a tertiary care hospital in Sweden.

2.1. Data collection and patient groups {#s0015}
---------------------------------------

All adult patients with COVID-19 consecutively admitted to the ICU March 13th to April 14th 2020 with informed consent and routinely performed TEG results accessible were included in the study. COVID-19 was diagnosed with positive reverse-transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swabs.

Dalteparin (Fragmin®, Pfizer AB, Sollentuna, Sweden) subcutaneously was used for thrombosis prophylaxis. COVID-19 patients with body weight below 70 kg were given 5000 IU dalteparin, those with body weight 70--90 kg were given 7500 IU dalteparin and those above 90 kg were given 10,000 IU dalteparin. The anti-factor Xa target range for thrombosis prophylaxis was 0.2--0.4 kIU/L. \[[@bb0055]\]

Clinical data were recorded prospectively daily. Simplified acute physiology score 3 (SAPS3) \[[@bb0060]\], renal function, circulatory support and respiratory support data were collected as reported in the results. Blood samples were collected on ICU admission and daily during the ICU stay. Blood count (CBC), high sensitivity C-reactive protein (CRP), kidney and liver function tests were performed. CBC was analyzed on a Sysmex XN™ instrument (Sysmex, Kobe, Japan) while hsCRP, ferritin, kidney and liver markers were analyzed on an Architect ci16200 (Abbott Laboratories, Abbott Park, IL, US).

2.2. Coagulation tests {#s0020}
----------------------

The viscoelastic properties were analyzed using the TEG 6 s® platform (Haemonetics, Boston, MA), \[[@bb0065]\] the citrated multichannel cartridge facilitates the simultaneous performance of the citrated kaolin (CK), citrated kaolin with heparinase (CKH), citrated rapidTEG® (CRT), and citrated functional fibrinogen (CFF) assays. R-time (R), angle (A), maximal amplitude (MA), and lysis at 30 min (Lys30) from the standard (kaolin) and heparinase curves were analyzed.

International Normalized Ratio (INR), activated partial thromboplastin time, anti-factor Xa and Fibrin D-dimer were all analyzed on a STA-R Max2 (Stago, Asnières-sur-Seine, France). The reagent used for the PK/INR method was STA SPA+ from Stago, Catalogue number 00330 STA. The reagent is used for determination of the combined Factors II, VII and X. Coagulation samples were taken every morning except anti-factor Xa which was taken approximately 4 h after subcutaneous injection of dalteparin. The limit of quantification for the anti-factor Xa assay was 0.1 kIU/L and the total coefficient of variation was 4.5% at 0.56 kIU/L. The limits of quantification for the D-dimer assay was 0.27 mg/L and the total coefficient of variation was 4.2% at 2.16 mg/L.

2.3. Statistical analysis {#s0025}
-------------------------

Continuous variables are presented as median (IQR, interquartile range) and categorical variables as number of observations (percent of total number of observations). Mann-Whitney *U* test was used for group comparisons and Spearman Rank to assess correlation between variables. Repeated tests were compared using Skillings-Mack test. A two-sided p \< .05 was considered significant. Calculations were performed using Statistica (version 13.2, Stat. Soft. Inc. Tulsa, OK, USA) and Stata (version 15.1, StataCorp, College Station, TX, USA).

3. Results {#s0030}
==========

A total of 31 patients diagnosed with COVID-19 treated in ICU were enrolled in the study. Characteristics of patients with and without thromboembolic events in the study cohort are listed in [Table 1](#t0005){ref-type="table"} . Most patients were male and the median BMI in the cohort was 30. One fourth of the cohort had a history of smoking, but ongoing smoking was unusual. The most common comorbidities were hypertension, diabetes mellitus and chronic lung disease.Table 1Patient demographic characteristics and comorbidities.Table 1All participantsNo TEAny TEn = 31n = 26n = 5Women, n (%)6 (19)6 (23)0 (0)Age65 (51--70)65 (51--71)51 (34--65)Body weight, kg85 (80--94)85 (80--94)84 (81--89)Height, cm173 (165--177)173 (165--177)171 (163--176)BMI, kg/m^2^30 (27--33)30 (26--33)30 (28--35)SAPS353 (48--60)55 (49--60)49 (48--50)COVID-19 day on arrival10 (8--12)10 (8--12)10 (9--10)  Comorbidities, n (%) Hypertension18 (58)16 (62)2 (40) Heart failure1 (3)1 (4)0 (0) Peripheral vessel disease4 (13)4 (15)0 (0) Previous thromboembolic event1 (3)1 (4)0 (0) Pulmonary disease8 (26)8 (31)0 (0) Diabetes mellitus9 (29)9 (35)0 (0) Malignancy1 (3)1 (4)0 (0)[^1][^2]

The median ICU admission was 10 days after the initial COVID-19 symptoms. During their ICU stay 24 patients (77%) were subjected to invasive ventilation and 25 patients (81%) were treated with vasopressors (noradrenalin) at some point.

Five patients developed clinical symptomatic thromboembolic events, (four with pulmonary embolism and one with deep vein thrombosis), all thromboembolic events diagnosed day 11--16 after onset of COVID-19 symptoms. No clinically significant bleeding was registered. Patients developing thromboembolism had a shorter activated partial thromboplastin time (APTT) and higher D-dimer compared to patients not developing thromboembolism. There were no differences in INR or platelet count. Comparison of coagulation markers are listed in [Table 2](#t0010){ref-type="table"} . Out of 31 patients included in the study, 20 had elevated MA on TEG. There were no differences in TEG variables in patients with or without thromboembolic events. All patients had a MA \> 65 mm, while 23 patients (74%) had MA \> 69 mm and 13 (42%) had MA \> 72 mm at some point during ICU stay. No signs of increased thrombolysis were seen.Table 2Inflammation and coagulation tests of patients at ICU admission.Table 2No TEAny TEp-valueReference rangen265CRP (mg/L)207 (117--269)143 (136--144).271\<5Ferritin, (μg/L)1159 (514--2607)1152 (676--1930).83025--310APTT (s)39 (35--48)33 (32--35).00130--42D-dimer (mg/L)1.1 (0.7--2.8)3.7 (2.0--6.6).039\<0.67INR1.1 (1.0--1.2)1.1 (1.0--1.1).3180.9--1.2Platelet count (x10^9^)196 (143--241)220 (157--224).830150--350  TEG R (s)7.2 (6.4--8.2)6.2 (5.3--7.7).3474.6--9.1 R~KCH~ (s)7.0 (6.2--7.7)6.5 (5.4--8.5).6284.3--8.0 Angle (deg)77 (76--79)76 (74--77).21663--78 MA (mm)70 (69--73)70 (68--70).51952--69 Lys30 (%)0.0 (0.0--0.2)0.0 (0.0--0.0).1060--2.6 MA outside reference range (\>69), n173[^3][^4]

No major changes were seen in laboratory variables during the ICU stay, except for decreasing CRP ([Table 3](#t0015){ref-type="table"} ).Table 3The evolution of inflammation and coagulation tests of patients during ICU stay.Table 3Day \<4Day 4--7Day \> 7p-valueMedian (IQR)nMedian (IQR)nMedian (IQR)nCRP (mg/L)214 (152--294)31252 (207--344)27100 (48--230)20\<.001Ferritin (μg/L)1257 (520--2645)301898 (794--2832)251559 (856--2974)17.001APTT (s)37 (34--41)1944 (42--48)1540 (37--49)11.068D-dimer (mg/L)2.1 (0.9--3.2)313.3 (1.9--4.3)273.0 (2.0--5.8)17.001INR1.1 (1.0--1.2)201.1 (1.0--1.1)131.1 (1.1--1.2)12.869Platelet count (x10^9^)227 (163--248)31358 (278--421)27457 (328--528)20\<.001Anti-factor Xa (kIE/L)0.2 (0.2--0.3)90.4 (0.3--0.4)130.4 (0.3--0.6)13.344  TEG R (s)7.3 (6.7--8.2)218.9 (7.3--10.6)118.1 (6.1--9.5)11.288 R~KCH~ (s)6.9 (6.2--7.7)218.3 (6.8--9.4)117.6 (5.7--10.1)11.580 Angle (deg)76 (75--78)2176 (69--80)1179 (77--81)11.326 MA (mm)69 (68--71)2171 (69--72)1171 (70--73)11.603 Lys300.0 (0.0--0.2)210.0 (0.0--0.0)110.0 (0.0--0.1)111.0[^5][^6]

In the patients without thromboembolic events, i.e. with prophylaxis dose of dalteparin, 6 of the 26 (23%) had an anti-factor Xa at least once below the target range, while 12 of 26 (46%) had and anti-factor Xa at least once above the target range. There was no correlation between dalteparin dose and anti-factor Xa ([Fig. 1](#f0005){ref-type="fig"} ).Fig. 1The association between dalteparin dose and anti-factor Xa in the cohort with corresponding Spearman rank correlation coefficient.Fig. 1

4. Discussion {#s0035}
=============

In this cohort study of 31 COVID-19 patients admitted to intensive care, a majority of patients show a hyper-coagulopathic phenotype during the course of illness. Further, standard prophylactic doses of LMWH may be insufficient to protect patients from thromboembolic complications. Analysis of anti-factor Xa activity and TEG appear inadequate to monitor the effect of LMWH in these patients.

The increased risk of thromboembolic complications in COVID-19 has been widely discussed, and early reports have indicated an associated coagulation abnormality predisposing thromboembolic disease. Standard coagulation parameters classically show marked elevation of fibrin-D-dimer, marginal increases in prothrombin time and slight thrombocytopenia \[[@bb0035]\]. In addition, Ranucci et al. recently demonstrated increased clot strength with significant platelet and fibrinogen contribution \[[@bb0070]\].

The present study reports the results of 31 patients using TEG, showing that hypercoagulability is a general feature across this population. This was seen in the form of increased maximum amplitude (MA) but not as a decreased R-time. This is in partial agreement with previous studies that have shown both decreased clot formation time and increased maximum amplitude \[[@bb0075],[@bb0080]\]. A greater than normal MA has been able to predict thromboembolism in trauma and postoperatively \[[@bb0085]\]. In orthopedic trauma patients the risk of developing venous thromboembolism increases already when MA ≥ 65 mm, and further doubles if MA ≥ 72 mm \[[@bb0090]\]. This can be compared to our results where all patients had MA ≥ 65 mm and 42% had MA ≥ 72 mm. However, MA was not different in patients with or without thromboembolic events. Our results also indicate a higher than usual incidence of thromboembolic disease compared to the standard ICU population \[[@bb0095]\]. Still, it is not in the range of early clinical reports describing patients with COVID-19 \[[@bb0005]\]. This may reflect rapid implementation of supra normal prophylactic dosing of LMWH in our ICU.

COVID-19 patients have several factors predisposing to thrombotic disease, including immobilization, inflammation, venous catheterization and sometimes complex underlying illness. LMWH reduces the risk of lower extremity deep vein thrombosis and pulmonary embolism in critically ill patients \[[@bb0095]\] and the International Society on Thrombosis and Haemostasis recommends the use of LMWH for all COVID-19 patients admitted to hospital \[[@bb0100]\]. LMWH exert their effect by augmenting the inhibiting impact on activated factor X and thrombin by antitrombin III. This can be monitored by measuring plasma levels of anti-factor Xa activity, as recommended when dosing may be difficult \[[@bb0105]\]. A substantial number of patients in the present cohort had sub-prophylactic LMWH activity compared to current recommendations \[[@bb0055]\] despite normal dosing. This may lead to the conclusion that measuring anti-factor X activation may be useful. However, our results indicate that COVID-19 may be associated with thromboembolic complications even with anti-factor Xa activation in the accepted prophylactic range. This prompts for vigilance as it suggests that it may be difficult to predict the risk of thromboembolic complications using standard tests, and equally hard to safely conclude that a patient has adequate treatment with LMWH.

Strengths of this study includes data from TEG with and without heparinase, allowing assessment of heparin effects. Weaknesses include the relatively low number of patients and events and the fact that a number of patients in the study still receive critical care.

5. Conclusion {#s0040}
=============

COVID-19 patients have hypercoagulability with high maximum amplitude (MA) on TEG, and often show insufficient effect of standard doses of LMWH. Our results suggest that neither anti-factor Xa activity nor TEG can reliably determine the effect of LMWH in patients with COVID-19. Further studies are needed to investigate the optimal dose of LMWH in these patients as well as potential alternative thrombosis prophylaxis.
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[^1]: BMI: Body mass index, COVID-19: Coronavirus disease 2019, IQR: Interquartile range, SAPS3: Simplified Acute Physiology Score, TE: thromboembolism.

[^2]: Median (IQR) or n (%).

[^3]: APTT: Activated partial thromboplastin time, CRP: C-reactive protein, INR: international normalized ratio, IQR: Interquartile range, KCH: kaolin with heparinase, Lys30: Clot lysis at 30 min, MA: maximum amplitude, R: reaction time, TE: thromboembolism, TEG: Thromboelastography.

[^4]: Median (IQR). p-value from Mann-Whitney U test.

[^5]: APTT: Activated partial thromboplastin time, CRP: C-reactive protein, INR: international normalized ratio, IQR: Interquartile range, KCH: kaolin with heparinase, Lys30: Clot lysis at 30 min, MA: maximum amplitude, R: reaction time, TEG: Thromboelastography.

[^6]: Median (IQR). p-value from Skillings-Mack test.
